drug_type
RELEVANT_DRUG
intervention_type
Drug
drug_description
A tumor-targeted superantigen fusion protein (anti-5T4 Fab linked to a bacterial superantigen) that binds 5T4 on tumor cells and polyclonally activates T cells via TCR Vβ engagement at the tumor site.
nci_thesaurus_concept_id
C95789
nci_thesaurus_definition
A recombinant fusion protein consisting of the antigen-binding fragment of a monoclonal antibody directed towards the tumor-associated oncofetal trophoblast glycoprotein antigen 5T4 attached to a mutated form of superantigen staphylococcal enterotoxin E (SEA/E-120), with immunomodulating and antineoplastic activities. The Fab moiety of naptumomab estafenatox binds to 5T4, an antigen expressed by various tumor cells. In turn, the superantigen binds to both major histocompatibility complex class II molecules and to the T-cell receptor beta chain, which results in a massive activation of T lymphocytes and induces a potent T-cell-mediated killing of tumor cells.
drug_mesh_term
naptumomab estafenatox
drug_category
BISPECIFIC T ENGAGER
drug_class
Engager
drug_delivery_route
Intravenous
drug_mechanism_of_action
A tumor‑targeted superantigen fusion protein in which an anti‑5T4 Fab directs the molecule to 5T4‑expressing tumor cells while the staphylococcal enterotoxin E (SEA/E‑120) moiety binds T‑cell receptors (TCR Vβ) and MHC class II, driving potent, polyclonal T‑cell activation at the tumor site and T‑cell–mediated killing of 5T4+ cancer cells.
drug_name
Naptumomab Estafenatox
nct_id_drug_ref
NCT05894447